沙利度胺治疗晚期软组织肉瘤的临床观察  

Clinical observation of thalidomide in treatment of patients with advanced soft tissue sarcoma

作　　者：蔡铭泉[1] 李晓虹[1] 张映红[1] 吕晓君[1] 

机构地区：[1]厦门大学附属第一医院肿瘤内科,福建厦门361003

出　　处：《临床肿瘤学杂志》2013年第2期169-171,共3页Chinese Clinical Oncology

摘　　要：目的评价沙利度胺单药治疗晚期软组织肉瘤的疗效、不良反应及对患者生活质量的影响。方法 22例二线方案化疗失败的晚期软组织肉瘤患者口服沙利度胺,每日100mg晚睡前顿服,1周后加量至每日200mg,维持治疗至疾病进展,同时每日口服阿斯匹林75mg。每2个月评价疗效、毒副反应,参照Karnofsky评分评价患者生活质量(QOL)。结果 2例获得PR(9.1%),4例SD(18.2%),疾病控制率(DCR)为27.3%;中位无进展生存期为1个月,中位总生存期为5个月;3例(13.6%)生活质量改善,5例(22.7%)稳定。主要不良反应为便秘、疲乏、嗜睡,多为1～2级,其他不良反应少见。结论单药沙利度胺治疗软组织肉瘤具有一定疗效,可提高部分患者的生活质量。Objective To evaluate the efficacy and side effects of thalidomide in the treatment of advanced soft tissue sarco- ma and impact on quality of life. Methods Twenty-two patients with advanced soft tissue sarcoma were given thalidomide 100rag per day and up to 200mg per day seven days later, at the same time patients were given aspirin 75mg per day orally. The efficacy, side effects and quality of life were evaluated every 2 months. Results Two （9. 1% ） patients had PR, four patients （ 18.2% ） had SD, and disease control rate was 27. 3%. Median time to progression was 1 month, median overall survival was 5 months, and the rate of improved quality of life was 13.6%. The main side effects were constipation, fatigue, somnolence, which were mostly in grade 1-2, and other adverse reactions were rare. Conclusion Thalidomide regimen as third-line treatment for patients with advanced soft tissue sarcoma is effective, and it can improve life quality, and the side effects can be tolerable.

关 键 词：沙利度胺 软组织肉瘤 药物疗法 

分 类 号：R738.6[医药卫生—肿瘤]